In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Prionics AG

Latest From Prionics AG

Amorfix Life Sciences Ltd.

Amorfix is an emerging life science company based in Toronto, Canada that is developing diagnostics and therapeutics for neurological disorders in which aggregated mis-folded proteins may be involved.
BioPharmaceutical Medical Device

How Big Can Bio-Rad Get?

Bio-Rad's having a great year, thanks to its presence in the fast-growing life sciences business of protein analysis, and its surprise success with a test for bovine spongiform encephalopathy (BSE). Founder and CEO David Schwartz built the business based on a mix of eclectic product lines into an $800 million force in life sciences and clinical diagnostics. But as he nears 80, the company is grappling with succession issues, as well as a sense that it needs to better integrate its disparate businesses.
BioPharmaceutical Medical Device

The Boom in Prion Testing

With concern growing about the spread of prion-based neurodegenerative diseases, the opportunity for new diagnostics tests seems clear. A number of start-ups and research labs are working on ways to diagnose these always fatal diseases, which occur in animals and, rarely, in humans. Three large in vitro diagnostics companies are teaming up with prion start-ups--indicating not only their faith in the market but also their ability to offer global distribution to small companies struggling to meet a demand that erupted abruptly.
Medical Device Business Strategies

Prionics AG

Mad cow disease, scrapie in sheep and Creutzfeldt-Jakob disease are members of a class of rare degenerative disease of the brain known as transmissible spongiform encephalopathies. TSE-infected animals have pathologically altered proteins called prions in their brains. Now, three sicentists from the University of Zurich have formed Prionics AG, to develop a sensitive test for prions using the abnormal protein as a marker for the disease.
BioPharmaceutical Medical Device
See All

Company Information

  • Industry
  • Biotechnology
  • In Vitro Diagnostics
  • Therapeutic Areas
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • Switzerland
  • Parent & Subsidiaries
  • Prionics AG
  • Senior Management
  • Bruno Odermatt, Head, Fin. & Admin.
    Bruno Oesch, Head, R&D
  • Contact Info
  • Prionics AG
    Phone: (41) 44 2002000
    Wagistrasse 27A
    Schlieren, CH 8952